Skip to main content

Peer Review reports

From: PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials

Original Submission
28 Oct 2021 Submitted Original manuscript
10 Mar 2022 Reviewed Reviewer Report
24 Mar 2022 Reviewed Reviewer Report
20 Jun 2022 Author responded Author comments - James Signorovitch
Resubmission - Version 2
20 Jun 2022 Submitted Manuscript version 2
22 Jun 2022 Author responded Author comments - James Signorovitch
Resubmission - Version 3
22 Jun 2022 Submitted Manuscript version 3
3 Jul 2022 Reviewed Reviewer Report
5 Jul 2022 Reviewed Reviewer Report
22 Aug 2022 Author responded Author comments - James Signorovitch
Resubmission - Version 4
22 Aug 2022 Submitted Manuscript version 4
24 Aug 2022 Author responded Author comments - James Signorovitch
Resubmission - Version 5
24 Aug 2022 Submitted Manuscript version 5
3 Sep 2022 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
5 Sep 2022 Editorially accepted
21 Sep 2022 Article published 10.1186/s12885-022-10078-5

You can find further information about peer review here.

Back to article page